{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:19:57Z","timestamp":1792801197679,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T00:00:00Z","timestamp":1546905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"PledPharma","id":[{"id":"https:\/\/ror.org\/03gsy3007","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13063-018-3134-1","type":"journal-article","created":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T12:20:27Z","timestamp":1546950027000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N-acetylcysteine for paracetamol overdose\u2014the PP100\u201301 for Overdose of Paracetamol (POP) trial: study protocol for a randomised controlled trial"],"prefix":"10.1186","volume":"20","author":[{"name":"The POP Trial Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8630-8625","authenticated-orcid":false,"given":"James","family":"Dear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,8]]},"reference":[{"issue":"6","key":"3134_CR1","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1111\/bcp.12779","volume":"80","author":"Hafid Narayan","year":"2015","unstructured":"Narayan H, Thomas SH, Eddleston M, Dear JW, Sandilands E, Nicholas Bateman D. Disproportionate effect on child admissions of the change in Medicines and Healthcare Products Regulatory Agency guidance for management of paracetamol poisoning: an analysis of hospital admissions for paracetamol overdose in England and Scotland. Br J Clin Pharmacol. 2015;80(6):1458-63.","journal-title":"British Journal of Clinical Pharmacology"},{"key":"3134_CR2","doi-asserted-by":"publisher","first-page":"f403","DOI":"10.1136\/bmj.f403","volume":"346","author":"K Hawton","year":"2013","unstructured":"Hawton K, Bergen H, Simkin S, Dodd S, Pocock P, Bernal W, Gunnell D, Kapur N. Long term effect of reduced pack sizes of paracetamol on poisoning deaths and liver transplant activity in England and Wales: interrupted time series analyses. BMJ. 2013;346:f403.","journal-title":"BMJ"},{"issue":"1","key":"3134_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/hep.20293","volume":"40","author":"WM Lee","year":"2004","unstructured":"Lee WM. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure. Hepatology. 2004;40(1):6\u20139.","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"3134_CR4","first-page":"157","volume":"3","author":"A Ramachandran","year":"2017","unstructured":"Ramachandran A, Jaeschke H. Mechanisms of acetaminophen hepatotoxicity and their translation to the human pathophysiology. J Clin Transl Res. 2017;3(Suppl 1):157\u201369.","journal-title":"J Clin Transl Res"},{"issue":"8035","key":"3134_CR5","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1016\/S0140-6736(77)90612-2","volume":"2","author":"LF Prescott","year":"1977","unstructured":"Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432\u20134.","journal-title":"Lancet"},{"issue":"6","key":"3134_CR6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/15563650701864760","volume":"46","author":"WS Waring","year":"2008","unstructured":"Waring WS, Stephen AF, Robinson OD, Dow MA, Pettie JM. Lower incidence of anaphylactoid reactions to N-acetylcysteine in patients with high acetaminophen concentrations after overdose. Clin Toxicol. 2008;46(6):496\u2013500.","journal-title":"Clin Toxicol"},{"key":"3134_CR7","unstructured":"Hospital Episode Statistics - \n                    http:\/\/www.hscic.gov.uk\/hes\n                    \n                  . Accessed 31 Dec 2018."},{"issue":"9918","key":"3134_CR8","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0140-6736(13)62062-0","volume":"383","author":"DN Bateman","year":"2014","unstructured":"Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M, Sandilands EA, Coyle J, Cooper JG, Rodriguez A, Butcher I, et al. Reduction of adverse effects from intravenous acetylcysteine treatment for paracetamol poisoning: a randomised controlled trial. Lancet. 2014;383(9918):697\u2013704.","journal-title":"Lancet"},{"issue":"5","key":"3134_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S0168-8278(03)00325-8","volume":"39","author":"S Bedda","year":"2003","unstructured":"Bedda S, Laurent A, Conti F, Chereau C, Tran A, Tran-Van Nhieu J, Jaffray P, Soubrane O, Goulvestre C, Calmus Y, et al. Mangafodipir prevents liver injury induced by acetaminophen in the mouse. J Hepatol. 2003;39(5):765\u201372.","journal-title":"J Hepatol"},{"issue":"3","key":"3134_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1006\/bbrc.1998.0131","volume":"254","author":"H Brurok","year":"1999","unstructured":"Brurok H, Ardenkjaer-Larsen JH, Hansson G, Skarra S, Berg K, Karlsson JO, Laursen I, Jynge P. Manganese dipyridoxyl diphosphate: MRI contrast agent with antioxidative and cardioprotective properties? Biochem Biophys Res Commun. 1999;254(3):768\u201372.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"3134_CR11","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1080\/0284186X.2017.1398836","volume":"57","author":"B Glimelius","year":"2018","unstructured":"Glimelius B, Manojlovic N, Pfeiffer P, Mosidze B, Kurteva G, Karlberg M, Mahalingam D, Buhl Jensen P, Kowalski J, Bengtson M, et al. Persistent prevention of oxaliplatin-induced peripheral neuropathy using calmangafodipir (PledOx((R))): a placebo-controlled randomised phase II study (PLIANT). Acta Oncol. 2018;57(3):393\u2013402.","journal-title":"Acta Oncol"},{"issue":"4 Pt 2","key":"3134_CR12","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1080\/02841859709172409","volume":"38","author":"D Grant","year":"1997","unstructured":"Grant D, Blazak WF, Brown GL. The reproductive toxicology of intravenously administered MnDPDP in the rat and rabbit. Acta Radiol. 1997;38(4 Pt 2):759\u201369.","journal-title":"Acta Radiol"},{"issue":"2","key":"3134_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S2468-1253(17)30266-2","volume":"3","author":"JW Dear","year":"2018","unstructured":"Dear JW, Clarke JI, Francis B, Allen L, Wraight J, Shen J, Dargan PI, Wood D, Cooper J, Thomas SHL, et al. Risk stratification after paracetamol overdose using mechanistic biomarkers: results from two prospective cohort studies. Lancet Gastroenterol Hepatol. 2018;3(2):104\u201313.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9263","key":"3134_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1016\/S0140-6736(00)04337-3","volume":"357","author":"D Moher","year":"2001","unstructured":"Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 2001;357(9263):1191\u20134.","journal-title":"Lancet"},{"key":"3134_CR15","doi-asserted-by":"publisher","first-page":"d2218","DOI":"10.1136\/bmj.d2218","volume":"342","author":"RE Ferner","year":"2011","unstructured":"Ferner RE, Dear JW, Bateman DN. Management of paracetamol poisoning. BMJ. 2011;342:d2218.","journal-title":"BMJ"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3134-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13063-018-3134-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-018-3134-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T19:21:58Z","timestamp":1578424918000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-018-3134-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,8]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3134"],"URL":"https:\/\/doi.org\/10.1186\/s13063-018-3134-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,8]]},"assertion":[{"value":"27 April 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"West of Scotland Research Ethics Committee 1, Glasgow, UK (approval 11 April 2017).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DH and MB are employed by PledPharma AB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"27"}}